NCT01153321View on ClinicalTrials.gov

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Chronic Obstructive Pulmonary DiseaseLung Disease
Interventions
DRUG

AZD2423

100mg Oral dose od

DRUG

AZD2423 Placebo

Oral dose od

Trial Locations (1)

Unknown

Research Site, Hanover

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY